原发性肝癌的早期筛查及诊断

陆伦根

doi:10.3969/j.issn.1001-5256.2017.07.010

原发性肝癌的早期筛查及诊断

DOI: 10.3969/j.issn.1001-5256.2017.07.010

陆伦根

上海交通大学附属第一人民医院消化科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3302
- HTML全文浏览量: 35
- PDF下载量: 607
- 被引次数: 0
出版历程
- 收稿日期: 2017-03-06
- 出版日期: 2017-07-20

Advances in early screening and diagnosis of hepatocellular carcinoma

Lu LunGen

Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University

摘要

摘要: 肝癌是我国死亡率位居第二的恶性肿瘤,每年死亡人数占全球肝癌死亡病例数的51%,给我国的社会和医疗带来了沉重的负担。早期诊断是预防肝癌、提高肝癌患者生存率最重要的措施之一,开发应用简单、方便、快捷的诊断方法是目前研究的努力方向。肝癌早期诊断的主要方法包括:影像学诊断、蛋白标志物检测、分子标志物检测等途径,其中AFP对肝癌的早期诊断有重要价值,AFP家庭自测的开展普及可实现患者的AFP定期监测,助力肝癌早诊,开创肝癌早筛早诊的新途径。
- 肝肿瘤 /
- 早期诊断 /
- 甲胎蛋白类
Abstract: Hepatocellular carcinoma (HCC) is a malignant tumor with the second highest mortality rate in China, and annual deaths account for 51% of all deaths in the world.HCC brings heavy burdens to the society and medical care in China.Early diagnosis is one of the most important methods for preventing HCC and improving survival rate of HCC patients, and the development of simple, convenient, and quick diagnostic methods is a direction for current research.Methods for the early diagnosis of HCC mainly include imaging diagnosis and measurements of protein markers and molecular markers.Alpha-fetoprotein (AFP) has an important value in the early diagnosis of HCC.One Step AFP test helps the patients to measure AFP at home by themselves and realize the regular monitoring of AFP level, which supports the early diagnosis of HCC and creates a new approach for early screening and diagnosis of HCC.
- liver neoplasms /
- early diagnosis /
- alpha-fetoproteins

HTML全文

参考文献(38)

[1]SHAO Y, GUAN JZ.Progress in treatment of primary liver cancer[J].Infect Dis Info, 2016, 29 (4) :248-252. (in Chinese) 邵艳, 管静芝.原发性肝癌治疗进展[J].传染病信息, 2016, 29 (4) :248-252.

[2]WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease:the major impact of China[J].Hepatology, 2014, 60 (6) :2099-2108.

[3]FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al.Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer, 2015, 136 (5) :e359-e386.

[4]ZHU RX, SETO WK, LAI CL, et al.Epidemiology of hepatocellular carcinoma in the Asia-Pacific region[J].Gut Liver, 2016, 10 (3) :332-339.

[5]LIU J, FAN D.Hepatitis B in China[J].Lancet, 2007, 369 (9573) :1582-1583.

[6]HASSAN MM, HWANG LY, HATTEN CJ, et al.Risk factors for hepatocellular carcinoma:synergism of alcohol with viral hepatitis and diabetes mellitus[J].Hepatology, 2002, 36 (5) :1206-1213.

[7]LYU GS, CHEN L, WANG HY, et al.Research progress and prospect of liver cancer in China[J].Chin Bull Life Sci, 2015, 27 (3) :237-247. (in Chinese) 吕桂帅, 陈磊, 王红阳, 等.我国肝癌研究的现状与前景[J].生命科学, 2015, 27 (3) :237-247.

[8]HUANG Y, YANG L.High-risk factors for primary liver cancer and early screening for subclinical liver cancer[J].J New Med, 2014, 24 (2) :73-78. (in Chinese) 黄颖, 杨玲.原发性肝癌的高危因素及亚临床型肝癌的早期筛查[J].医学新知杂志, 2014, 24 (2) :73-78.

[9]KANWAL F, KRAMER JR, ILYAS J, et al.HCV Genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S.veterans with HCV[J].Hepatology, 2014, 60 (1) :98-105.

[10]FATTOVICH G, STROFFOLINI L, ZAGNI L, et al.Hepatocellular carcinoma in cirrhosis:incidence and risk factors[J].Gastroenterology, 2004, 127 (5) :s35-s50.

[11]REIN DB, WITTENBORN JS, WEINBAUM CM, et al.Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States[J].Dig Liver Dis, 2011, 43 (1) :66-72.

[12]KOHLI A, SHAFFER A, SHERMAN A, et al.Treatment of hepatitis C:a systematic review[J].Jama, 2014, 312 (6) :631-640.

[13]BRESSAC B, KEW M, WANDS J, et al.Seletive G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa[J].Nature, 1991, 350 (6317) :429-431.

[14]LI XD, WANG YW, HU J.Progress on epigenetic research of liver cancer[J].Mod Oncol, 2016, 24 (9) :1501-1504. (in Chinese) 李晓东, 王运帷, 胡静.肝癌的表观遗传学研究进展[J].现代肿瘤医学, 2016, 24 (9) :1501-1504.

[15]WANG Z, LIU L, JI J, et al.ABO blood group system and gastric cancer:a case-control study and meta-analysis[J].Int J Mol Sci, 2012, 13 (10) :13308-13321.

[16]RISCH HA, LU L, WANG J, et al.ABO group and risk of pancreatic cancer:a study in Shanghai and meta-analysis[J].Am J Epidemiol, 2013, 177 (12) :1326-1337.

[17]JOH HK.CHO E.CHOUEIRI TK.ABO group and risk of renal cell cancer[J].Cancer epidemiology, 2012, 36 (6) :528-532.

[18]FUKUMOTO K, TANIGUCHI T, USAMI N, et al.The ABO blood group is an independent prognostic factor in patients with resected non-small cell lung cancer[J].J Epidemiol, 2015, 25 (2) :110-116.

[19]GAO S, YANG WS, GAO J, et al.A Meta-analysis of cohort studies on the association between diabetes and the risk of primary liver cancer[J].Chin J Prevent Med, 2010, 44 (8) :711-716. (in Chinese) 高姗, 杨万水, 高静, 等.糖尿病与原发性肝癌队列研究的Meta分析[J].中华预防医学杂志, 2010, 44 (8) :711-716.

[20]CHEN Y, WANG XL, WANG JH, et al.Excess body weight and the risk of primary liver cancer:an updated meta-analysis of prospective studies[J].European J Cancer, 2012, 48 (14) :2137-2145.

[21]JING Z, GONG L, ZOU CL, et al.A case-control study on relationship between attack of primary hepatocellar carcinoma and psychological factors[J].Chin J Primary Med Pharm, 2007, 14 (6) :923-924. (in Chinese) 景钊, 龚玲, 邹长林, 等.肝癌发病与心理因素关系的病例对照研究[J].中国基层医药, 2007, 14 (6) :923-924.

[22]ZHOU X.Clinical value of combined detection of multiple serum markers in early diagnosis of hepatocellular carcinoma[J].Chin Health Stand Manage, 2016, 21 (7) :138-139. (in Chinese) 周筱.多种血清标志物联合检测对肝癌早期诊断的临床价值[J].中国卫生标准管理, 2016, 21 (7) :138-139.

[23]HUANG SJ, LOU JL.Progress of the diagnosis methods for hepatocellular carcinoma[J].Labeled Immunoassay Clin Med, 2016, 23 (4) :466-469. (in Chinese) 黄述婧, 娄金丽.肝癌诊断技术方法应用进展[J].标记免疫分析与临床, 2016, 23 (4) :466-469.

[24]di MARTINO M, de FILIPPIS G, de SANTIS A, et al.Hepatocellular carcinoma in cirrhotic patients:prospective comparison of US, CTand MR imaging[J].Euro Radiol, 2013, 23 (4) :887-896.

[25]CHEN ML, ZHANG XY, QI LP, et al.Diffusion-weighted images (DWI) without ADC values in assessment of small focal nodules in cirrhotic liver[J].Chin J Cancer Res, 2014, 26 (1) :38-47.

[26]FU SJ, QI CY, XIAO WK, et al.Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection[J].Surgery, 2013, 154 (3) :536-544.

[27]WANG Y, YANG H, XU H, et al.Golgi protein 73, not Glypican-3, may be a tumor marker complementary toα-Fetoprotein for hepatocellular carcinoma diagnosis[J].J Gastroenterol Hepatol, 2014, 29 (3) :597-602.

[28]SHANG S, PLYMOTH A, GE S, et al.Identification of osteopontin as a novel marker for early hepatocellular carcinoma[J].Hepatology, 2012, 55 (2) :483-490.

[29]ZHENG Y.Clinical studies of OPN and VEGF in primary hepatocellular carcinoma[D].Jinan:Shandong Univ, 2012. (in Chinese) 郑艳.骨桥蛋白与血管内皮生长因子在原发性肝癌中表达的临床意义研究[D].济南:山东大学, 2012.

[30]YU B, YANG X, XU Y, et al.Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas[J].J Hepatol, 2009, 50 (5) :948-957.

[31]LIN Y, ZHANG YL, HU X, et al.Molecular mechanism and function research of highly expressed FEG10 gene in hepatocellular carcinoma[J].Tumor, 2013, 33 (1) :28-35.

[32]FENG D, WANG N, HU J, et al.Surface markers of hepatocellular cancer stem cells and their clinical potential[J].Neoplasm, 2014, 61 (5) :505-513.

[33]BOYE A, YANG Y.Hepatic microRNA orchestra:a new diagnostic, prognostic and theranostic tool for hepatecarcinogenesis[J].Mini Rev Med Chem, 2014, 14 (10) :837-852.

[34]HUO Q, ZHENG ZH, LIU J, et al.Diagnosis value of combined detection of serum golgi protein 73, desgamma carboxy prothrombin andγ-fetoprotein in primary hepatic carcinoma[J].Natl Med JChina, 2015, 95 (10) :756-760. (in Chinese) 霍群, 郑泽辉, 刘杰, 等.高尔基体蛋白73及去γ-羧基凝血酶原联合甲胎蛋白检测对肝癌的诊断价值[J].中华医学杂志, 2015, 95 (10) :756-760.

[35]TANG XQ.Application of chemiluminescent enzyme immu-noassay for tumor markers in primary liver cancer[J].Lab Med Clin, 2013, 10 (19) :2580-2581.

[36] ERTLE JM, HEIDER D, WICHERT M, et al.A combination ofα-fetoprotein and des-γ-carboxy prothrombin is supe-rior in detection of hepatocellular carcinoma[J].Digestion, 2013, 87 (2) :121-131.

[37]XIAO ZH, MENG G, WANG LZ.Diagnositic value of combined detection of 4 tumor markers in primary hepatocellular carcinoma[J].Pract J Cancer, 2015, 30 (3) :345-347.

[38]CHEN JG, LU JH, ZHU YR, et al.A thirty-one year prospective follw-up program on the HBs Ag carrier state and primary liver cancer in Qidong, China[J].Chin J Epidemiol, 2010, 31 (7) :721-726. (in Chinese) 陈建国, 陆建华, 朱源荣, 等.乙型肝炎病毒感染与肝癌发生的31年随访研究[J].中华流行病学杂志, 2010, 31 (7) :721-726.

施引文献

资源附件(0)

访问统计